Yipinhong Pharmaceutical Co Ltd Class A Cash Flow Conversion Efficiency
Yipinhong Pharmaceutical Co Ltd Class A cash flow conversion efficiency. Based on the latest financial reports, Yipinhong Pharmaceutical Co Ltd Class A (300723) has a cash flow conversion efficiency ratio of 0.008x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥14.81 Million ≈ $2.17 Million USD) by net assets (CN¥1.80 Billion ≈ $263.56 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Yipinhong Pharmaceutical Co Ltd Class A (2013–2025)
Cash flow conversion efficiency of Yipinhong Pharmaceutical Co Ltd Class A from 2013 to 2025. This chart illustrates how Yipinhong Pharmaceutical Co Ltd Class A's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Yipinhong Pharmaceutical Co Ltd Class A for real-time trading data and today's change.
Yipinhong Pharmaceutical Co Ltd Class A Cash Flow Conversion Ratio Explained
Yipinhong Pharmaceutical Co Ltd Class A cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Yipinhong Pharmaceutical Co Ltd Class A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Yipinhong Pharmaceutical Co Ltd Class A ranked by their cash flow conversion efficiency. Also see 300723 company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
COUNTRY GARDEN SVDL-0001
F:75H
|
N/A |
|
SIRIUS REAL ESTATE LTD.
F:EYI
|
N/A |
|
Tatung Co
TW:2371
|
-0.009x |
|
Himax Technologies Inc
NASDAQ:HIMX
|
0.019x |
|
Kent Gida Maddeleri Sanayi ve Ticaret AS
IS:KENT
|
-0.536x |
|
German American Bancorp Inc
NASDAQ:GABC
|
0.048x |
|
ALPEK S.A.B. de C.V
MX:ALPEKA
|
0.099x |
|
EMEIS SA
PA:EMEIS
|
0.441x |
Annual Cash Flow Conversion Efficiency for Yipinhong Pharmaceutical Co Ltd Class A (2013–2025)
The table below shows the annual cash flow conversion efficiency of Yipinhong Pharmaceutical Co Ltd Class A from 2013 to 2025. Review how much free cash does Yipinhong Pharmaceutical Co Ltd Class A generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥1.41 Billion ≈ $205.84 Million |
CN¥46.01 Million ≈ $6.73 Million |
0.033x | +111.50% |
| 2024-12-31 | CN¥1.94 Billion ≈ $283.28 Million |
CN¥-550.42 Million ≈ $-80.54 Million |
-0.284x | -261.26% |
| 2023-12-31 | CN¥2.60 Billion ≈ $380.16 Million |
CN¥458.05 Million ≈ $67.03 Million |
0.176x | -19.70% |
| 2022-12-31 | CN¥2.17 Billion ≈ $316.92 Million |
CN¥475.53 Million ≈ $69.59 Million |
0.220x | +1.16% |
| 2021-12-31 | CN¥2.02 Billion ≈ $295.35 Million |
CN¥438.10 Million ≈ $64.11 Million |
0.217x | +17.91% |
| 2020-12-31 | CN¥1.50 Billion ≈ $218.77 Million |
CN¥275.22 Million ≈ $40.27 Million |
0.184x | -12.06% |
| 2019-12-31 | CN¥1.34 Billion ≈ $196.17 Million |
CN¥280.65 Million ≈ $41.07 Million |
0.209x | +14.00% |
| 2018-12-31 | CN¥1.30 Billion ≈ $190.13 Million |
CN¥238.60 Million ≈ $34.91 Million |
0.184x | +44.01% |
| 2017-12-31 | CN¥1.11 Billion ≈ $162.20 Million |
CN¥141.35 Million ≈ $20.68 Million |
0.128x | -70.61% |
| 2016-12-31 | CN¥336.50 Million ≈ $49.24 Million |
CN¥146.01 Million ≈ $21.37 Million |
0.434x | +152.00% |
| 2015-12-31 | CN¥200.66 Million ≈ $29.36 Million |
CN¥34.55 Million ≈ $5.06 Million |
0.172x | +151.17% |
| 2014-12-31 | CN¥127.52 Million ≈ $18.66 Million |
CN¥8.74 Million ≈ $1.28 Million |
0.069x | -90.62% |
| 2013-12-31 | CN¥185.61 Million ≈ $27.16 Million |
CN¥135.68 Million ≈ $19.85 Million |
0.731x | -- |
About Yipinhong Pharmaceutical Co Ltd Class A
ApicHope Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in China. The company offers pediatric medicines; chronic disease drugs; active pharmaceutical ingredients and formulations; and specialty traditional Chinese medicines. It is also involved in scientific research and technical services; wholesale a… Read more